JP2017537137A - Pargの阻害剤としての2,4−ジオキソ−キナゾリン−6−スルホンアミド誘導体 - Google Patents
Pargの阻害剤としての2,4−ジオキソ−キナゾリン−6−スルホンアミド誘導体 Download PDFInfo
- Publication number
- JP2017537137A JP2017537137A JP2017531303A JP2017531303A JP2017537137A JP 2017537137 A JP2017537137 A JP 2017537137A JP 2017531303 A JP2017531303 A JP 2017531303A JP 2017531303 A JP2017531303 A JP 2017531303A JP 2017537137 A JP2017537137 A JP 2017537137A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- sulfonamide
- dioxo
- quinazoline
- methylcyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(*)C(*)(*C(*)=**=C(*=NNC2=O)C2=I)C1(*)* Chemical compound CC1(*)C(*)(*C(*)=**=C(*=NNC2=O)C2=I)C1(*)* 0.000 description 22
- UVOCFNHECJYOTE-UHFFFAOYSA-N CC(C)C(c(c1c2)ccc2SCc2ccccc2)=NNC1=O Chemical compound CC(C)C(c(c1c2)ccc2SCc2ccccc2)=NNC1=O UVOCFNHECJYOTE-UHFFFAOYSA-N 0.000 description 1
- KNVQOJCBABICPE-UHFFFAOYSA-N CC(C1)(C1[O]=S(c(cc1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(C(F)F)C2=O)=O)N Chemical compound CC(C1)(C1[O]=S(c(cc1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(C(F)F)C2=O)=O)N KNVQOJCBABICPE-UHFFFAOYSA-N 0.000 description 1
- DPZFRGQIBRKRJK-UHFFFAOYSA-N CC(C1)(C1[O]=S(c(cc1)cc(C(N2Cc3ccn[s]3)=O)c1N(C)C2=O)=O)N Chemical compound CC(C1)(C1[O]=S(c(cc1)cc(C(N2Cc3ccn[s]3)=O)c1N(C)C2=O)=O)N DPZFRGQIBRKRJK-UHFFFAOYSA-N 0.000 description 1
- ZGJAUTIYHMSDOV-UHFFFAOYSA-N CC(C1)(C1[O]=S(c(cc1Br)cc(C(N2Cc3c[n](C)nc3)=O)c1NC2=O)=O)N Chemical compound CC(C1)(C1[O]=S(c(cc1Br)cc(C(N2Cc3c[n](C)nc3)=O)c1NC2=O)=O)N ZGJAUTIYHMSDOV-UHFFFAOYSA-N 0.000 description 1
- MOXLVHRHSSLRML-UHFFFAOYSA-N CC(C1)(C1[O]=S(c(cc1C(N2Cc3nnc(C)[s]3)=O)ccc1N(Cc1cc(C)n[n]1C)C2=O)=O)N Chemical compound CC(C1)(C1[O]=S(c(cc1C(N2Cc3nnc(C)[s]3)=O)ccc1N(Cc1cc(C)n[n]1C)C2=O)=O)N MOXLVHRHSSLRML-UHFFFAOYSA-N 0.000 description 1
- NUJZXRKVWFOHTF-UHFFFAOYSA-N CC(C1)(C1[O]=[S+](c(cc1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(CC(F)(F)F)C2=O)=O)N Chemical compound CC(C1)(C1[O]=[S+](c(cc1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(CC(F)(F)F)C2=O)=O)N NUJZXRKVWFOHTF-UHFFFAOYSA-N 0.000 description 1
- OMATZKVGBSVQDN-UHFFFAOYSA-N CC(C1)(C1[O]=[S+](c(cc1C(O)=O)cc(C(N2Cc3c[n](C)nc3)=O)c1NC2=O)=O)N Chemical compound CC(C1)(C1[O]=[S+](c(cc1C(O)=O)cc(C(N2Cc3c[n](C)nc3)=O)c1NC2=O)=O)N OMATZKVGBSVQDN-UHFFFAOYSA-N 0.000 description 1
- ZJAZYZRRSFJRPZ-UHFFFAOYSA-N CC1(C=2C1)NS=2(c(cc1)cc(C(OC)=O)c1Br)=O Chemical compound CC1(C=2C1)NS=2(c(cc1)cc(C(OC)=O)c1Br)=O ZJAZYZRRSFJRPZ-UHFFFAOYSA-N 0.000 description 1
- ZDWFPYYLBQYJMU-UHFFFAOYSA-N CC1(CC1)NS(c(c(F)c1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(Cc1c(C)nc(C)[s]1)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(c(F)c1)cc(C(N2Cc3c[n](C)nc3)=O)c1N(Cc1c(C)nc(C)[s]1)C2=O)(=O)=O ZDWFPYYLBQYJMU-UHFFFAOYSA-N 0.000 description 1
- LZKMKAANVVIQJT-UHFFFAOYSA-N CC1(CC1)NS(c(cc(C(NC)=O)c(N)c1)c1F)(=O)=O Chemical compound CC1(CC1)NS(c(cc(C(NC)=O)c(N)c1)c1F)(=O)=O LZKMKAANVVIQJT-UHFFFAOYSA-N 0.000 description 1
- ACJVKXPMEBMIMO-UHFFFAOYSA-N CC1(CC1)NS(c(cc1)cc(N(C)C2=O)c1N(Cc(cc1)ccc1F)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc(N(C)C2=O)c1N(Cc(cc1)ccc1F)C2=O)(=O)=O ACJVKXPMEBMIMO-UHFFFAOYSA-N 0.000 description 1
- OWFAXOVJLHCBIV-UHFFFAOYSA-N CC1(CC1)NS(c(cc1)cc2c1C(C)=NN(Cc1cc(C)n[o]1)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc2c1C(C)=NN(Cc1cc(C)n[o]1)C2=O)(=O)=O OWFAXOVJLHCBIV-UHFFFAOYSA-N 0.000 description 1
- QSCLKNXALFPYKR-UHFFFAOYSA-N CC1(CC1)NS(c(cc1)cc2c1C=CN(Cc1cc(C)n[o]1)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1)cc2c1C=CN(Cc1cc(C)n[o]1)C2=O)(=O)=O QSCLKNXALFPYKR-UHFFFAOYSA-N 0.000 description 1
- BTXVZOKRJCFZLE-UHFFFAOYSA-N CC1(CC1)NS(c(cc12)ccc1C(c(cc1)ccc1F)=CN(C)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc12)ccc1C(c(cc1)ccc1F)=CN(C)C2=O)(=O)=O BTXVZOKRJCFZLE-UHFFFAOYSA-N 0.000 description 1
- DWJSTVHLGJJEAO-UHFFFAOYSA-N CC1(CC1)NS(c(cc1C(N2C3CC3)=O)ccc1NC2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1C(N2C3CC3)=O)ccc1NC2=O)(=O)=O DWJSTVHLGJJEAO-UHFFFAOYSA-N 0.000 description 1
- NMOOMFFVYDOWSD-UHFFFAOYSA-N CC1(CC1)NS(c(cc1C(N2CCC3NC=CC=C3)=O)ccc1N(C)C2=O)(=O)=O Chemical compound CC1(CC1)NS(c(cc1C(N2CCC3NC=CC=C3)=O)ccc1N(C)C2=O)(=O)=O NMOOMFFVYDOWSD-UHFFFAOYSA-N 0.000 description 1
- ZFOPUDLNZKRABN-UHFFFAOYSA-N CC1NN(C)C=C1CN(C(c(cc(cc1)S(NC2(CF)CC2)(=O)=O)c1N1CC2COCC2)=O)C1=O Chemical compound CC1NN(C)C=C1CN(C(c(cc(cc1)S(NC2(CF)CC2)(=O)=O)c1N1CC2COCC2)=O)C1=O ZFOPUDLNZKRABN-UHFFFAOYSA-N 0.000 description 1
- XHAILOKUGDPYDF-GQCTYLIASA-N CN(C(/C(/CC1Br)=C/C=C)=O)N=C1Cl Chemical compound CN(C(/C(/CC1Br)=C/C=C)=O)N=C1Cl XHAILOKUGDPYDF-GQCTYLIASA-N 0.000 description 1
- CQUKPUDLJXBEPN-UHFFFAOYSA-N CN(C(c1c2ccc(Br)c1)=O)N=C2Cl Chemical compound CN(C(c1c2ccc(Br)c1)=O)N=C2Cl CQUKPUDLJXBEPN-UHFFFAOYSA-N 0.000 description 1
- OHAKJDAFXOXSJC-UHFFFAOYSA-N COC(C(c(c1c2)ccc2SCc2ccccc2)=NNC1=O)=O Chemical compound COC(C(c(c1c2)ccc2SCc2ccccc2)=NNC1=O)=O OHAKJDAFXOXSJC-UHFFFAOYSA-N 0.000 description 1
- CJRHLSZJEFJDLA-UHFFFAOYSA-N COC(c(cc(cc1)Br)c1I)=O Chemical compound COC(c(cc(cc1)Br)c1I)=O CJRHLSZJEFJDLA-UHFFFAOYSA-N 0.000 description 1
- KQQRMNWGPDZCLY-UHFFFAOYSA-N C[n]1c(CN(c(ccc(S(NC2(CF)CC2)(=O)=O)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)ncc1 Chemical compound C[n]1c(CN(c(ccc(S(NC2(CF)CC2)(=O)=O)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)ncc1 KQQRMNWGPDZCLY-UHFFFAOYSA-N 0.000 description 1
- AOGONHHEZGGBCV-UHFFFAOYSA-N C[n]1nc(CN(C(c2cc([S+](=O)=[O]C(C3)C3(CF)N)ccc2N2C)=O)C2=O)cn1 Chemical compound C[n]1nc(CN(C(c2cc([S+](=O)=[O]C(C3)C3(CF)N)ccc2N2C)=O)C2=O)cn1 AOGONHHEZGGBCV-UHFFFAOYSA-N 0.000 description 1
- MCUNCOSXZBMCTD-UHFFFAOYSA-N C[n]1ncc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3c[n](C)nn3)=O)C2=O)c1 Chemical compound C[n]1ncc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3c[n](C)nn3)=O)C2=O)c1 MCUNCOSXZBMCTD-UHFFFAOYSA-N 0.000 description 1
- PHRVXMHNWDPZGZ-UHFFFAOYSA-N C[n]1ncc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3ccncc3)=O)C2=O)c1 Chemical compound C[n]1ncc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3ccncc3)=O)C2=O)c1 PHRVXMHNWDPZGZ-UHFFFAOYSA-N 0.000 description 1
- YRONSGRLAXMUNK-UHFFFAOYSA-N C[n]1ncc(CN(C(c(cc(cc2)[S+](=O)=[O]C(C3)C3(CF)N)c2N2CCOCCOC)=O)C2=O)c1 Chemical compound C[n]1ncc(CN(C(c(cc(cc2)[S+](=O)=[O]C(C3)C3(CF)N)c2N2CCOCCOC)=O)C2=O)c1 YRONSGRLAXMUNK-UHFFFAOYSA-N 0.000 description 1
- RAPRXBRGLWJJRK-UHFFFAOYSA-N C[n]1ncc(CN(C(c(cc(cc2)[S+](=O)=[O]C(C3)C3(CF)N)c2N2Cc3cccc(F)n3)=O)C2=O)c1 Chemical compound C[n]1ncc(CN(C(c(cc(cc2)[S+](=O)=[O]C(C3)C3(CF)N)c2N2Cc3cccc(F)n3)=O)C2=O)c1 RAPRXBRGLWJJRK-UHFFFAOYSA-N 0.000 description 1
- IOEAPTGDEYRNCZ-UHFFFAOYSA-N C[n]1ncc(CN(c(ccc([S+](=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)c1 Chemical compound C[n]1ncc(CN(c(ccc([S+](=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)c1 IOEAPTGDEYRNCZ-UHFFFAOYSA-N 0.000 description 1
- UCDRHJNKPHCIQW-UHFFFAOYSA-N Cc1cc(CN(c(ccc(S(=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)ncc1 Chemical compound Cc1cc(CN(c(ccc(S(=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)ncc1 UCDRHJNKPHCIQW-UHFFFAOYSA-N 0.000 description 1
- QDMIVCPXBNGAIL-UHFFFAOYSA-N Cc1n[n](C)c(CN(c(ccc([S+](=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)n1 Chemical compound Cc1n[n](C)c(CN(c(ccc([S+](=O)=[O]C(C2)C2(CF)N)c2)c2C(N2Cc3c[n](C)nc3)=O)C2=O)n1 QDMIVCPXBNGAIL-UHFFFAOYSA-N 0.000 description 1
- SLLGHKSOVHEGHK-UHFFFAOYSA-N Cc1n[o]c(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3ncn[n]3C)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3ncn[n]3C)=O)C2=O)c1 SLLGHKSOVHEGHK-UHFFFAOYSA-N 0.000 description 1
- QGBMZMNQXYKVAJ-UHFFFAOYSA-N Cc1n[o]c(CN(C(c(cc(cc2)S(NC3(CC3)C#N)(=O)=O)c2N2)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c(cc(cc2)S(NC3(CC3)C#N)(=O)=O)c2N2)=O)C2=O)c1 QGBMZMNQXYKVAJ-UHFFFAOYSA-N 0.000 description 1
- LGPWGUZGKMFVFX-UHFFFAOYSA-N Cc1n[o]c(CN(C(c(cc(cc2)S(NC3(CF)CC3)(=C)=O)c2N2Cc3nnc(C)[s]3)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c(cc(cc2)S(NC3(CF)CC3)(=C)=O)c2N2Cc3nnc(C)[s]3)=O)C2=O)c1 LGPWGUZGKMFVFX-UHFFFAOYSA-N 0.000 description 1
- UKNPJACMJOBONV-UHFFFAOYSA-N Cc1n[o]c(CN(C(c(cc(cc2C)S(Cl)(=O)=O)c2N2C)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c(cc(cc2C)S(Cl)(=O)=O)c2N2C)=O)C2=O)c1 UKNPJACMJOBONV-UHFFFAOYSA-N 0.000 description 1
- KCQGISFLTSZYHR-UHFFFAOYSA-N Cc1n[o]c(CN(C(c2c3)=O)N=C(CC4CC4)c2ccc3S(Oc(c(F)c(c(F)c2F)F)c2F)(=O)=O)c1 Chemical compound Cc1n[o]c(CN(C(c2c3)=O)N=C(CC4CC4)c2ccc3S(Oc(c(F)c(c(F)c2F)F)c2F)(=O)=O)c1 KCQGISFLTSZYHR-UHFFFAOYSA-N 0.000 description 1
- MAZQHJLRJMPTKK-UHFFFAOYSA-N Cc1n[o]c(CN(C(c2c3)=O)N=C(CC4CCCCC4)c2ccc3S(Oc(c(F)c(c(F)c2F)F)c2F)(=O)=O)c1 Chemical compound Cc1n[o]c(CN(C(c2c3)=O)N=C(CC4CCCCC4)c2ccc3S(Oc(c(F)c(c(F)c2F)F)c2F)(=O)=O)c1 MAZQHJLRJMPTKK-UHFFFAOYSA-N 0.000 description 1
- UHYJEYUJGRDWJF-UHFFFAOYSA-N Cc1n[o]c(CN(C(c2c3)=O)N=C(Cc4ccccc4)c2ccc3SCc2ccccc2)c1 Chemical compound Cc1n[o]c(CN(C(c2c3)=O)N=C(Cc4ccccc4)c2ccc3SCc2ccccc2)c1 UHYJEYUJGRDWJF-UHFFFAOYSA-N 0.000 description 1
- AHJKUNAKXXYWJL-UHFFFAOYSA-N Cc1n[o]c(CN(C(c2ccccc2N2)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c2ccccc2N2)=O)C2=O)c1 AHJKUNAKXXYWJL-UHFFFAOYSA-N 0.000 description 1
- GHSGRLBUSNVDQC-UHFFFAOYSA-N Cc1n[o]c(CN(C(c2ccccc2N2C)=O)C2=O)c1 Chemical compound Cc1n[o]c(CN(C(c2ccccc2N2C)=O)C2=O)c1 GHSGRLBUSNVDQC-UHFFFAOYSA-N 0.000 description 1
- MLXIETQCWGZSNP-UHFFFAOYSA-N Cc1n[s]c(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2C)=O)C2=O)c1 Chemical compound Cc1n[s]c(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2C)=O)C2=O)c1 MLXIETQCWGZSNP-UHFFFAOYSA-N 0.000 description 1
- DESZBCYMKNHDIV-UHFFFAOYSA-N Cc1nnc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2)=O)C2=O)[s]1 Chemical compound Cc1nnc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2)=O)C2=O)[s]1 DESZBCYMKNHDIV-UHFFFAOYSA-N 0.000 description 1
- FBNZYZRAHBSRPV-UHFFFAOYSA-N Cc1nnc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3c[n](C)nc3)=O)C2=O)[s]1 Chemical compound Cc1nnc(CN(C(c(cc(cc2)S(=O)=[O]C(C3)C3(CF)N)c2N2Cc3c[n](C)nc3)=O)C2=O)[s]1 FBNZYZRAHBSRPV-UHFFFAOYSA-N 0.000 description 1
- FJCOUBLATCMSGZ-UHFFFAOYSA-N O=C(c(cc1)c2cc1Br)NN=C2Cl Chemical compound O=C(c(cc1)c2cc1Br)NN=C2Cl FJCOUBLATCMSGZ-UHFFFAOYSA-N 0.000 description 1
- KPWFZUDXIWZJDT-UHFFFAOYSA-N O=C(c1c2)NN=C(CC3CCC3)c1ccc2Br Chemical compound O=C(c1c2)NN=C(CC3CCC3)c1ccc2Br KPWFZUDXIWZJDT-UHFFFAOYSA-N 0.000 description 1
- YPNYRYBDPWNDFC-UHFFFAOYSA-N O=C(c1c2)NN=C(CC3CCCCC3)c1ccc2Br Chemical compound O=C(c1c2)NN=C(CC3CCCCC3)c1ccc2Br YPNYRYBDPWNDFC-UHFFFAOYSA-N 0.000 description 1
- SDFFBYXRBNFUQT-UHFFFAOYSA-N O=C(c1c2ccc(Br)c1)NN=C2Cl Chemical compound O=C(c1c2ccc(Br)c1)NN=C2Cl SDFFBYXRBNFUQT-UHFFFAOYSA-N 0.000 description 1
- YRWRDWYNNLDIAJ-UHFFFAOYSA-N O=C(c1cc(Br)ccc11)NC=C1Cl Chemical compound O=C(c1cc(Br)ccc11)NC=C1Cl YRWRDWYNNLDIAJ-UHFFFAOYSA-N 0.000 description 1
- DSOKREQUHLPVFR-UHFFFAOYSA-N O=C1NC=Cc(cc2)c1cc2Br Chemical compound O=C1NC=Cc(cc2)c1cc2Br DSOKREQUHLPVFR-UHFFFAOYSA-N 0.000 description 1
- BRYVPUMGFKLXHV-UHFFFAOYSA-N O=C1NN=C(Cc2ccccc2)c(cc2)c1cc2Br Chemical compound O=C1NN=C(Cc2ccccc2)c(cc2)c1cc2Br BRYVPUMGFKLXHV-UHFFFAOYSA-N 0.000 description 1
- XRXMNWGCKISMOH-UHFFFAOYSA-N OC(c1ccccc1Br)=O Chemical compound OC(c1ccccc1Br)=O XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1422098.2 | 2014-12-12 | ||
GB201422098 | 2014-12-12 | ||
PCT/GB2015/053883 WO2016092326A1 (fr) | 2014-12-12 | 2015-12-11 | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017537137A true JP2017537137A (ja) | 2017-12-14 |
Family
ID=54937266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017531303A Pending JP2017537137A (ja) | 2014-12-12 | 2015-12-11 | Pargの阻害剤としての2,4−ジオキソ−キナゾリン−6−スルホンアミド誘導体 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10239843B2 (fr) |
EP (1) | EP3230273A1 (fr) |
JP (1) | JP2017537137A (fr) |
KR (1) | KR20170093967A (fr) |
CN (1) | CN107207467A (fr) |
AU (1) | AU2015359082A1 (fr) |
BR (1) | BR112017012402A2 (fr) |
CA (1) | CA2969296A1 (fr) |
IL (1) | IL252575A0 (fr) |
MA (1) | MA41140A (fr) |
MX (1) | MX2017007478A (fr) |
RU (1) | RU2017124425A (fr) |
SG (1) | SG11201704686UA (fr) |
WO (1) | WO2016092326A1 (fr) |
ZA (1) | ZA201704382B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138812A1 (fr) * | 2020-12-24 | 2022-06-30 | モジュラス株式会社 | Composé de tétrahydrothiénopyridinesulfonamide |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
US9624219B2 (en) | 2015-04-21 | 2017-04-18 | Glaxosmithkline Intellectual Property Development Limited | Compound (S) and (R)-N-(2-fluoropyridin-4-yl)-3-methyl-2-(5-methyl-2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidin-3(4H)-yl)butanamide and use |
WO2023057394A1 (fr) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
WO2023154913A1 (fr) * | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | Inhibiteurs de parg |
WO2023165571A1 (fr) * | 2022-03-04 | 2023-09-07 | 上海璎黎药业有限公司 | Composé contenant une structure cyclique hétéroaromatique à cinq chaînons, composition pharmaceutique et utilisation associées |
WO2023175185A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer |
WO2023175184A1 (fr) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer |
WO2023208092A1 (fr) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Dérivés hétérocycliques tricycliques, compositions et utilisations de ceux-ci |
WO2023224998A1 (fr) * | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | Inhibiteurs de parg |
US11939335B2 (en) | 2022-05-17 | 2024-03-26 | 858 Therapeutics, Inc. | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG |
WO2024017306A1 (fr) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | Composé cyclique hétéroaromatique contenant du soufre, composition pharmaceutique de celui-ci et son utilisation |
EP4311829A1 (fr) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer |
WO2024074497A1 (fr) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Composé inhibiteur de parg |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1157858A (fr) * | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Derives de quinazoline |
DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US7009052B2 (en) * | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
PT1719773E (pt) | 2004-02-24 | 2009-06-03 | Japan Tobacco Inc | Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv |
WO2007014226A2 (fr) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Composes pour le traitement de neurodegenerescence et d'accident cerebro-vasculaire |
DK1979314T3 (da) | 2006-01-24 | 2013-02-04 | Lilly Co Eli | Indolsulfonamidmodulatorer af progesteronreceptorer |
EP1998777A1 (fr) * | 2006-03-20 | 2008-12-10 | F. Hoffmann-La Roche AG | Procédés d'inhibition des protéines kinase btk et syk |
WO2009047255A1 (fr) * | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Composés hétérobicycliques utiles comme antagonistes du récepteur h4 de l'histamine |
CA2728098A1 (fr) | 2008-07-17 | 2010-01-21 | Asahi Kasei Pharma Corporation | Composes tricycliques contenant du pyrazole en tant qu'antagonistes du recepteur ep1 |
CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
WO2011140442A1 (fr) | 2010-05-07 | 2011-11-10 | Glaxo Group Limited | Amino-quinoléines en tant qu'inhibiteurs de kinase |
US8946260B2 (en) * | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
US8623889B2 (en) * | 2010-12-17 | 2014-01-07 | Genentech, Inc. | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
EP2471363A1 (fr) * | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes |
WO2013027168A1 (fr) * | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
WO2013067300A1 (fr) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Méthode de traitement |
JP2014106019A (ja) | 2012-11-26 | 2014-06-09 | Stack Electronics Co Ltd | プローブ |
EA201591220A1 (ru) | 2012-12-27 | 2016-01-29 | Дрексел Юниверсити | Новые противовирусные агенты против инфекции вирусом гепатита в |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
-
2015
- 2015-12-10 MA MA041140A patent/MA41140A/fr unknown
- 2015-12-11 JP JP2017531303A patent/JP2017537137A/ja active Pending
- 2015-12-11 KR KR1020177019260A patent/KR20170093967A/ko unknown
- 2015-12-11 MX MX2017007478A patent/MX2017007478A/es unknown
- 2015-12-11 WO PCT/GB2015/053883 patent/WO2016092326A1/fr active Application Filing
- 2015-12-11 US US15/533,804 patent/US10239843B2/en active Active
- 2015-12-11 CA CA2969296A patent/CA2969296A1/fr not_active Abandoned
- 2015-12-11 RU RU2017124425A patent/RU2017124425A/ru not_active Application Discontinuation
- 2015-12-11 BR BR112017012402A patent/BR112017012402A2/pt not_active Application Discontinuation
- 2015-12-11 AU AU2015359082A patent/AU2015359082A1/en not_active Abandoned
- 2015-12-11 CN CN201580075728.3A patent/CN107207467A/zh active Pending
- 2015-12-11 EP EP15813508.7A patent/EP3230273A1/fr not_active Withdrawn
- 2015-12-11 SG SG11201704686UA patent/SG11201704686UA/en unknown
-
2017
- 2017-05-29 IL IL252575A patent/IL252575A0/en unknown
- 2017-06-28 ZA ZA2017/04382A patent/ZA201704382B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138812A1 (fr) * | 2020-12-24 | 2022-06-30 | モジュラス株式会社 | Composé de tétrahydrothiénopyridinesulfonamide |
Also Published As
Publication number | Publication date |
---|---|
CN107207467A (zh) | 2017-09-26 |
CA2969296A1 (fr) | 2016-06-16 |
MA41140A (fr) | 2017-10-17 |
ZA201704382B (en) | 2019-09-25 |
KR20170093967A (ko) | 2017-08-16 |
IL252575A0 (en) | 2017-07-31 |
US10239843B2 (en) | 2019-03-26 |
BR112017012402A2 (pt) | 2017-12-26 |
SG11201704686UA (en) | 2017-07-28 |
RU2017124425A (ru) | 2019-01-14 |
EP3230273A1 (fr) | 2017-10-18 |
US20180016242A1 (en) | 2018-01-18 |
MX2017007478A (es) | 2018-05-04 |
AU2015359082A1 (en) | 2017-06-29 |
WO2016092326A1 (fr) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10995073B2 (en) | PARG inhibitory compounds | |
US10239843B2 (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | |
JP5551689B2 (ja) | ピリジン化合物 | |
US20210008023A1 (en) | N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | |
JP5178534B2 (ja) | キノリン誘導体 | |
JP7202315B2 (ja) | ベンズイミダゾロン由来のbcl6阻害剤 | |
WO2014060112A1 (fr) | Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases | |
IL199019A (en) | History of acylaminopyrazole, processes for their preparation, and their use in drug production | |
KR20070032810A (ko) | 포스포티딜이노시톨(pi) 3―키나제 저해제로서의2,4,6―삼치환 피리미딘 및 암 치료에서의 그의 용도 | |
JP2012529513A (ja) | トリアジン誘導体類及びそれらの治療応用 | |
MX2008008945A (en) | Morpholino pyrimidine derivatives and their use in therapy | |
KR20070032064A (ko) | 포스포티딜이노시톨(pi) 3-키나제 저해제로서의2,4,6-삼치환 피리미딘 및 암 치료에 있어서의 이의 용도 |